The influence of sodium bromide in man: a study in human volunteers with special emphasis on the endocrine and the central nervous system.
Sodium bromide was administered orally in capsules to healthy volunteers in doses of 0, 4 or 9 mg Br-/kg/day using a double-blind design. Each treatment was given to seven males for 12 weeks and to seven non-pregnant females (not using oral contraceptives) over three full cycles. Special attention was paid to possible effects on the endocrine and central nervous systems. At the start and end of the study, a full medical history, the results of a physical examination, haematological studies and standard clinical chemistry and urine analyses were recorded for each subject. These showed no changes for individuals following treatment, except for some incidence of nausea associated with bromide-capsule ingestion. Mean plasma-bromide concentrations at the end of treatment were 0.08, 2.14 and 4.30 mmol/litre for males and 0.07, 3.05 and 4.93 mmol/litre for females of the 0-, 4- and 9-mg Br-/kg/day groups, respectively. Plasma half-life was about 10 days. In the females taking 9 mg Br-/kg/day (but in no other group) there was a significant (P less than 0.01) increase in serum thyroxine and triiodothyronine between the start and end of the study but all concentrations remained within normal limits. No changes were observed in serum concentrations of free thyroxine, thyroxine-binding globulin, cortisol, oestradiol, progesterone or testosterone, or of thyrotropin, prolactin, luteinizing hormone (LH) and follicle-stimulating hormone before or after the administration of thyrotropin-releasing hormone and LH-releasing hormone. Analysis of neurophysiological data (EEG and visual evoked response) showed a decrease in delta 1- and delta 2-activities and increases in beta-activities and in mean frequency (Mobility parameter) in the groups on 9 mg Br-/kg/day, but all the findings were within normal limits.
D000328:Adult; D001965:Bromides / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity*; D002214:Capsules; D002490:Central Nervous System / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography; D004702:Endocrine Glands / Q000187:drug effects*; D005074:Evoked Potentials, Visual / Q000187:drug effects; D005260:Female; D006728:Hormones / Q000097:blood; D006801:Humans; D008297:Male; D008598:Menstruation / Q000187:drug effects; D012964:Sodium / Q000008:administration & dosage / Q000633:toxicity*; D017670:Sodium Compounds; D013997:Time Factors
D001965:Bromides; D002214:Capsules; D006728:Hormones; D017670:Sodium Compounds; D012964:Sodium; C027938:sodium bromide